Capital Expenditures - Fujian Cosunter Pharmaceutical Co Ltd (SZSE:300436) - Alpha Spread
F

Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436

Watchlist Manager
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Watchlist
Price: 17.97 CNY -2.5% Market Closed
Market Cap: 2.9B CNY
Have any thoughts about
Fujian Cosunter Pharmaceutical Co Ltd?
Write Note

Fujian Cosunter Pharmaceutical Co Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fujian Cosunter Pharmaceutical Co Ltd
Capital Expenditures Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
F
Fujian Cosunter Pharmaceutical Co Ltd
SZSE:300436
Capital Expenditures
-ÂĄ134m
CAGR 3-Years
-20%
CAGR 5-Years
3%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Capital Expenditures
-ÂĄ219.6m
CAGR 3-Years
46%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Capital Expenditures
-ÂĄ103.9m
CAGR 3-Years
37%
CAGR 5-Years
-6%
CAGR 10-Years
4%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Capital Expenditures
-ÂĄ1.5B
CAGR 3-Years
-9%
CAGR 5-Years
-25%
CAGR 10-Years
-14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Capital Expenditures
-ÂĄ548.5m
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
-27%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Capital Expenditures
-ÂĄ81.9m
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Fujian Cosunter Pharmaceutical Co Ltd's Capital Expenditures?
Capital Expenditures
-134m CNY

Based on the financial report for Mar 31, 2024, Fujian Cosunter Pharmaceutical Co Ltd's Capital Expenditures amounts to -134m CNY.

What is Fujian Cosunter Pharmaceutical Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
3%

Over the last year, the Capital Expenditures growth was 40%. The average annual Capital Expenditures growth rates for Fujian Cosunter Pharmaceutical Co Ltd have been -20% over the past three years , 3% over the past five years .

Back to Top